210962-44-0

Upstream product

• 120-47-8 Ethyl 4-hydroxybenzoate 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 1972-28-7 diethylazodicarboxylate 

Downstream Products

• 460365-21-3 C₁₄H₁₉NO₃ 
• 950649-16-8 4-(4-carboxyethylphenyloxy)-piperidine-1-carboxylic acid 2,4-dichloro-benzylamide 
• 321337-38-6 tert-butyl 4-(4-(hydroxymethyl)phenoxy)piperidine-1-carboxylate 
• 538335-94-3 methyl 2-acetamido-3-[2-(2R)-2-[4-(1-tert-butoxycarbonylpiperidyl-4-oxy)benzoylamino-3-benzyloxycarbonylpropoxy]-4-cyanophenyl]acrylate 
• 538335-97-6 methyl 2-acetamido-3-[4-amidino-2-[(2R)-3-ethoxycarbonyl-2-[4-(piperidyl-4-oxy)benzoylamino]propoxy]phenyl]acrylate 
• 538335-90-9 methyl 2-acetamido-3-[2-[2-[4-(1-tert-butoxycarbonyl-4-piperidyloxy)benzoylamino]ethoxy]-4-cyanophenyl]acrylate 
• 538336-04-8 ethyl 3-[2-[2-[(1-acetimidoyl-4-piperidyloxy)benzoylamino]ethoxy]-4-amidinophenyl]acrylate 
• 252261-63-5 ethyl 3-[2-[2-[(1-acetimidoyl-4-piperidyloxy)benzoylamino]ethoxy]-4-amidinophenyl]propionate 
• 538336-01-5 ethyl 3-[2-[2-[4-(1-tert-butoxycarbonyl-4-piperidyloxy)benzoylamino]ethoxy]-4-cyanophenyl]acrylate 
• 1026523-08-9 ethyl 3-[2-[2-[4-(4-piperidyloxy)benzoylamino]ethoxy]-4-amidinophenyl]acrylate 
• 210962-73-5 N-[2-(3-cyanophenoxy)ethyl]-4-(1-tert-butoxycarbonyl-4-piperidyloxy)benzamide 

Relevant academic research and scientific papers

DIAZANAPHTHALEN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF

Diazanaphthalene compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a diazanaphthalene compound or analogs thereof, in the treatment of disorders characterized by the activa

6-(6-MEMBERED HETEROARYL and ARYL)ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF

Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, inflammation, auto-immune diseases and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF

Isoquinoline compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an isoquinoline compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Pyridizinone derivatives

The present invention provides compounds of formula (I*): their use as H3 inhibitors, processes for their preparation, and pharmaceutical compositions thereof.

QUINAZOLINE DERIVATIVE

This invention provides a compound or its pharmaceutically-acceptable salt of formula (I) wherein R 1 represents a lower alkyl group et al; R 2 and R 3 are same and different and represents hydrogen atm et al; R 4 represents the substituent of the formula (II) et al; X 1 represents NH, O or S; Y represents N or C; Ar is a divalent substituent derived from aryl et al, by removing two hydrogen atoms therefrom; the ring A represents a 5- or 6-membered heteroaryl group; this compounds has a histamine-H3 receptor antagonistic effect or a histamine-H3 receptor inverse-agonistic effect and is useful for preventive or remedy of metabolic system diseases, circulatory system diseases or nervous system diseases.

SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHODS OF USING SAME

Disclosed are compounds active against soluble epoxide hydrolase (sEH), compositions thereof and methods of using and making same.

Rational design, synthesis, and structure-activity relationships of novel factor Xa inhibitors: (2-substituted-4-amidinophenyl)pyruvic and -propionic acids

An inhibitor of factor Xa (fXa), the m-substituted benzamidine AXC1578 (1a), was structurally modified with the aim of increasing its potency. In particular, pyruvic acid and propionic acid substituents were incorporated into the P1 benzamidine moiety to

Benzamidine derivatives

Benzamidine derivatives of the following formula, analogs thereof and pharmaceutically acceptable salts thereof are provided. These compounds have an effect of inhibiting activated blood-coagulation factor X, and they are useful as agents for preventing or treating various diseases caused by thrombi or emboli.

AMINOISOQUINOLINE DERIVATIVES

Aminoisoquinoline derivatives represented by formulae (I and II), analogs thereof or pharmaceutically acceptable salts of the same. Because of having excellent inhibitory effects on activated blood coagulation factor X, these compounds are useful as active ingredients in anticoagulants or preventives/remedies for thrombosis or embolism.

BENZAMIDINE DERIVATIVES

Benzamidine derivatives of the following formulae or analogs thereof, i. e., pharmaceutically acceptable salts thereof, are provided. These compounds or salts thereof have a blood-coagulation inhibiting effect based on an excellent effect of inhibiting the action of activated blood coagulation factor X, and they are useful as anticoagulants.